Cardiff Oncology (NASDAQ:CRDF) Price Target Lowered to $10.00 at HC Wainwright

Key Points

• HC Wainwright has reduced its price target for Cardiff Oncology from $18.00 to $10.00, indicating a potential upside of 289.11% from the stock's previous close despite maintaining a "buy" rating.
• Cardiff Oncology reported a quarterly loss of ($0.21) EPS, missing analysts' expectations, and posted a negative net margin of 9,344.14%.
• Insider purchases included Director Gary W. Pace acquiring 275,000 shares at an average price of $2.45, raising his ownership in the company by 26.05%.

Cardiff Oncology (NASDAQ:CRDF - Free Report) had its price target trimmed by HC Wainwright from $18.00 to $10.00 in a report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Cardiff Oncology's Q3 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.85) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.25) EPS and FY2026 earnings at ($0.95) EPS.

Other analysts also recently issued research reports about the company. William Blair restated an "outperform" rating on shares of Cardiff Oncology in a report on Wednesday, June 18th. Jefferies Financial Group began coverage on shares of Cardiff Oncology in a research note on Tuesday, June 24th. They issued a "hold" rating and a $3.50 price objective for the company. Finally, LADENBURG THALM/SH SH assumed coverage on shares of Cardiff Oncology in a research note on Tuesday, July 8th. They set a "buy" rating and a $19.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Cardiff Oncology currently has an average rating of "Moderate Buy" and a consensus price target of $10.10.

Cardiff Oncology Stock Down 0.8%

NASDAQ:CRDF traded down $0.02 during trading hours on Wednesday, reaching $2.39. 1,231,296 shares of the company's stock were exchanged, compared to its average volume of 3,188,633. The company has a market capitalization of $159.00 million, a P/E ratio of -2.75 and a beta of 1.54. Cardiff Oncology has a 12 month low of $2.09 and a 12 month high of $5.64. The business's 50-day simple moving average is $3.52 and its two-hundred day simple moving average is $3.46.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.11 million. Cardiff Oncology had a negative return on equity of 77.94% and a negative net margin of 9,344.14%. As a group, sell-side analysts anticipate that Cardiff Oncology will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Cardiff Oncology

In other news, Director Gary W. Pace acquired 275,000 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The stock was acquired at an average cost of $2.45 per share, for a total transaction of $673,750.00. Following the completion of the acquisition, the director owned 1,330,676 shares in the company, valued at approximately $3,260,156.20. The trade was a 26.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.70% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CRDF. BNP Paribas Financial Markets bought a new stake in shares of Cardiff Oncology in the 4th quarter valued at approximately $25,000. Baader Bank Aktiengesellschaft acquired a new stake in Cardiff Oncology in the second quarter valued at approximately $32,000. Ledgewood Wealth Advisors LLC bought a new stake in Cardiff Oncology in the first quarter worth approximately $35,000. ProShare Advisors LLC acquired a new position in shares of Cardiff Oncology during the 4th quarter worth $50,000. Finally, Belpointe Asset Management LLC bought a new position in shares of Cardiff Oncology during the 1st quarter valued at $37,000. 16.29% of the stock is owned by institutional investors and hedge funds.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.